BioCentury | Feb 19, 2021
Finance

Evox eyes clinic for internal pipeline with £69.2M series C round

...the company’s 2016 A round, also participated in the series C alongside OrbiMed, Invus, GV, Cowen Healthcare Investments...
BioCentury | Feb 11, 2021
Product Development

Feb. 10 Quick Takes: Softly goes PacBio; plus PGDx, Nuvation Bio, Gamida, Portal Innovations

...biopsy company Personal Genome Diagnostics Inc. raised $103 million in a series C round led by Cowen Healthcare Investments...
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

...Ventures, AV8 Ventures and Windham Venture Partners, and new investors including Foresite Capital, Northpond Ventures, Cowen Healthcare Investments...
BioCentury | Jan 6, 2021
Product Development

Propelled by Ionis deal, Aro raises $88M series A to advance targeted oligo pipeline

...Biotherapeutics Co. raised an $88 million series A round Tuesday led by Northpond Ventures and Cowen Healthcare Investments...
BioCentury | Jan 5, 2021
Finance

Immuneering, Terns, Ikena raise crossover rounds as IPO queue stands to grow again

...Capital, Invus, Farallon Capital Management, BVF Partners, Cowen Healthcare Investments...
BioCentury | Dec 17, 2020
Deals

Novartis to build out neuropsychiatry pipeline via Cadent takeout

...Inc. and emerged from stealth in late 2018 with a $40 million series B led by Cowen Healthcare Investments...
BioCentury | Dec 16, 2020
Emerging Company Profile

With crossover funding already in place, Stagliano’s Neuron23 exits stealth with programs in neurology, systemic immune disease

...the Opportunity 1 fund.Neuron23’s series B round included Cowen Healthcare Investments...
...Westlake Village BioPartners, Kleiner Perkins, Redmile Group, Cowen Healthcare Investments...
BioCentury | Aug 13, 2020
Finance

F2G raises $60.8M to get new class of antifungal to market

...it could become the first new antifungal in two decades, according to the company.New investor Cowen Healthcare Investments...
BioCentury | Jun 30, 2020
Finance

Syncona’s Freeline mulls IPO after crossovers back gene therapy play

...C round now includes contributions from Novo Holdings A/S, Eventide Asset Management, Wellington Management Co., Cowen Healthcare Investments...
BioCentury | Jun 25, 2020
Deals

June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla

...Limulus participated in the financing, along with existing investors OrbiMed Advisors, F-Prime Capital, Borealis Ventures, Cowen Healthcare Investments...
Items per page:
1 - 10 of 54
BioCentury | Feb 19, 2021
Finance

Evox eyes clinic for internal pipeline with £69.2M series C round

...the company’s 2016 A round, also participated in the series C alongside OrbiMed, Invus, GV, Cowen Healthcare Investments...
BioCentury | Feb 11, 2021
Product Development

Feb. 10 Quick Takes: Softly goes PacBio; plus PGDx, Nuvation Bio, Gamida, Portal Innovations

...biopsy company Personal Genome Diagnostics Inc. raised $103 million in a series C round led by Cowen Healthcare Investments...
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

...Ventures, AV8 Ventures and Windham Venture Partners, and new investors including Foresite Capital, Northpond Ventures, Cowen Healthcare Investments...
BioCentury | Jan 6, 2021
Product Development

Propelled by Ionis deal, Aro raises $88M series A to advance targeted oligo pipeline

...Biotherapeutics Co. raised an $88 million series A round Tuesday led by Northpond Ventures and Cowen Healthcare Investments...
BioCentury | Jan 5, 2021
Finance

Immuneering, Terns, Ikena raise crossover rounds as IPO queue stands to grow again

...Capital, Invus, Farallon Capital Management, BVF Partners, Cowen Healthcare Investments...
BioCentury | Dec 17, 2020
Deals

Novartis to build out neuropsychiatry pipeline via Cadent takeout

...Inc. and emerged from stealth in late 2018 with a $40 million series B led by Cowen Healthcare Investments...
BioCentury | Dec 16, 2020
Emerging Company Profile

With crossover funding already in place, Stagliano’s Neuron23 exits stealth with programs in neurology, systemic immune disease

...the Opportunity 1 fund.Neuron23’s series B round included Cowen Healthcare Investments...
...Westlake Village BioPartners, Kleiner Perkins, Redmile Group, Cowen Healthcare Investments...
BioCentury | Aug 13, 2020
Finance

F2G raises $60.8M to get new class of antifungal to market

...it could become the first new antifungal in two decades, according to the company.New investor Cowen Healthcare Investments...
BioCentury | Jun 30, 2020
Finance

Syncona’s Freeline mulls IPO after crossovers back gene therapy play

...C round now includes contributions from Novo Holdings A/S, Eventide Asset Management, Wellington Management Co., Cowen Healthcare Investments...
BioCentury | Jun 25, 2020
Deals

June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla

...Limulus participated in the financing, along with existing investors OrbiMed Advisors, F-Prime Capital, Borealis Ventures, Cowen Healthcare Investments...
Items per page:
1 - 10 of 54